Angiogenesis, the development of new blood vessels, is a fundamental physiological process. It also plays a critical role in a variety of different pathologic conditions, including tumor growth and metastasis. New blood vessels in tumors can grow by sprouting from pre-existing vessels or by recruitment of rare, circulating bone marrow-derived endothelial progenitor cells. A variety of different angiogenesis stimulators and inhibitors have been discovered including VEGF, integrin and Semaphorins. Angiogenic switch which cause a switch from the anti- to pro-angiogenic state depends on genetic and environmental factors. Antiangiogenic therapy is one of the promising tumor therapies that target tumor vasculature or angiogenic factors as VEGF-targeted therapy, integrin targeting agents and vascular disrupting agents.